The interactions of CD40 and CD40L have been known for some time to critically regulate Bcell responses with respect to proliferation, isotype switching, antibody production, and memory formation. More recent findings demonstrated that CD40 can be expressed on several other antigen-presenting cell (APC) types such as macrophages, dendritic cells, and fibroblasts. This expression of CD40 regulates T-cell-APC interaction and is centrally involved in a wide array of inflammatory events. Here, currently available data are reviewed demonstrating that CD40-CD40L interactions are operational in two chronic inflammatory clinical conditions, namely, multiple sclerosis and atherosclerosis. The functional correlates of these interactions are discussed in the light of recent other findings, shedding light on the multiple effects of CD40-CD40L interactions.
MULTIPLE ROLES OF CD40-CD40 LIGAND INTERACTIONS
The past 4 years have seen such a flurry of papers on the multiple and diverse roles of the CD40-CD40L receptor pair (reviewed in detail by Laman et al., 1996; Van Kooten and Banchereau, 1996) that the interaction of these two molecules has recently been likened to a "master regulator" of the immune system . However, this notion has been challenged by findings that some antiviral functions of CD4 T cells can be primed in a CD40-deficient environment (Oxenius et al., 1996) . Another aspect of T-cell function is the finding that thymic epithelium expresses CD40, and that CD40L is involved in thymic selection of T cells (Foy et al., 1995) . Antibody against CD40L can also inhibit the development of murine AIDS (Green et al., 1996) , a viral disease targeting B cells. In addition, CD40L is required for an effective antiviral memory CD8 Tcell response (Borrow et al., 1996) . With respect to autoimmune disease, anti-CD40L can interfere with disease development in mouse models for arthritis (Durie et al., 1993) , systemic lupus erythematosus (Mohan et al., 1995; Early et al., 1996) , and with disease in a mouse model for multiple sclerosis (MS) (Gerritse et al., 1996) (Wiley and Harmsen, 1995) and Leishmania species Kamanaka et al., 1996; Soong et al., 1996) .
In (Gerritse et al., 1996) . Development of disease could be effectively blocked when antibody was coadministered with immunization for disease induction, but also when treatment was started several days after immunization. However, treatment was not effective during the later stages of established disease. These data argued that CD40-CD40L interactions are crucial for development of EAE, and that they operate at some point prior to manifestation of clinical signs.
To confirm a role of CD40-CD40L interactions in MS, we performed immunocytochemistry on frozen sections from autopsy material. Both abundant expression of CD40 and limited expression of CD40L could be demonstrated within perivascular inflammatory infiltrates of mononuclear cells in situ (Gerritse et al., 1996) . Double-staining experiments for membrane expression of CD40 and intracytoplasmic activity of acid phosphatase showed that the large majority of cells expressing CD40 within inflammatory infiltrates belonged to the monocytic lineage. However, a minor fraction of the cells locally expressing CD40 could be identified as B cells as they also contained immunoglobulins (Gerritse et al., 1996) . Currently, we are addressing the mechanisms by which anti-CD40L antibody treatment prevents disease in mice. In these experiments, we have found that CD40 is also expressed in the spinal cord of mice with EAE (Laman et al., manuscript in preparation) . Using CD40L-deficient mice carrying a transgenic Tcell receptor for myelin basic protein (MBP), Grewal et al. (1996) confirmed our previous observations in anti-CD40L-treated mice, and extended these findings by showing that adoptive transfer of B7-1 APC could overcome the defect and supported production of IFN-y and development of EAE. Collectively, the data in mice and humans support the view that CD40-CD40L interactions are essential in these chronic inflammatory conditions and imply that novel therapeutic strategies could be developed with this in mind.
With the aim to develop animal models applicable to evaluate therapeutics suitable for use in humans, we analyzed expression of CD40, CD40L, B7-1, B7-2, and a panel of pro-and anti-inflammatory cytokines in the nonhuman primate marmoset species (Callithrix jacchus) (Laman et al., in press, b). Five marmosets were immunized with myelin purified from human white matter and suffered from attacks of acute EAE, corroborating earlier findings (Massacesi et al., 1995 Table I ), thereby improving extravasation of mononuclear cells. CD40-CD40L interaction can mediate production of metalloproteinase (MMP-I: collagenase) by T cells, which may improve transmigration of T cells (Dollery et al., 1995; Miltenburg et al., 1995) .
Signals through CD40L are required for T-cell priming in several experimental settings (Grewal et al., 1995; Van Essen et al., 1995;  reviewed by , but not others (Oxenius et al., 1996) . Expression of CD40 on APC either in the periphery or within mononuclear cell infiltrates (on macrophages) of the CNS in MS and EAE may serve this purpose. Peng et al. (1996) have shown that triggering T cells through CD40L leads to production of both Thl and Th2 cytokines in vitro (see Table 1 ). A study by Vergelli et al. (1996) demonstrated that a novel population of CD4+CD56 myelin-reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. It will be of interest to determine whether these cells express CD40L and whether ligation influences lytic activity.
Autoantibodies contribute to development of MS and EAE. T-B-cell interaction guided by CD40- (Gerritse et al., 1993 (Gerritse et al., , 1994 . Macrophages can potentially contribute to myelin loss and local inflammation in many ways, including (auto)-antigen presentation, production of cytokines and chemokines, proteolytic enzymes, nitric oxide, reactive oxygen species, and lipid peroxidation. In vivo depletion studies of macrophages have confirmed the requirement for this cell type in development of EAE (Huitinga et al., 1995) . In addition, transgenic mice expressing the macrophage/microglia cytokine gene IL-3 in astrocytes show infiltration of macrophages but not lymphocytes, in conjunction with primary demyelination and motor deficits (Chiang et al., 1996) . The role of macrophages is further supported by the finding that neutralization of the macrophage inflammatory protein-a (MIP-1 c) inhibits disease (Karpus et al., 1995) .
Macrophage functions relevant to MS and EAE that can be triggered through CD40 include improved APC function through upregulation of ICAM-1, MHC class II, CD86, and CD40 itself ; production of proinflammatory cytokines (TNF-a, ILl/3, IL-6, IL-8, and IL-12p40) (Alderson et al., 1993;  Wagner et al., 1994; Kiener et al., 1995; Shu et al., 1995; Kato et al., 1996 ) (see also (1996) have shown that the same antibody we used to prevent EAE in mice (Gerritse et al., 1996) inhibits IL-12 production and thereby may prevent priming of T cells. Interestingly, two recent papers have shown that mouse dendritic cells produced high levels of IL-12 in response to CD40L, even in the absence of cognate antigen recognition (Cella et al., 1996; Koch et al., 1996) . In addition, links exist between CD40L expression and production of IL-12 and NO, both in EAE and in cell-mediated immunity against Pneumocystis carinii (Wiley and Harmsen, 1995) and Leishmania species Kamanaka et al., 1996; Soong et al., 1996) . (Laman et al., 1997) . This disease results from an extremely complex and only partly understood interplay among diverse components such as cholesterol metabolism, hemodynamic stress, the blood coagulation system, and risk factors such as obesity and smoking. The immune system is critically involved in atherosclerosis, as evidenced by high numbers of activated T cells and macrophages within atherosclerotic plaques (Hansson and Libby, 1996; Raines et al., 1996) , and the involvement of mononuclear cells in production of cytokines and growth factors (Libby and Ross, 1996) .
To assess the hypothesis that CD40-CD40L interactions play a role in atherosclerosis, we analyzed the expression of CD40 by means of immunohistochemistry on frozen sections from human plaque material. Atherosclerosis patients were surgically treated to remove plaques from the carotid artery (endarterectomy). CD40 was expressed in different regions of the plaque, and by cell types with distinct morphologies ( Fig. lc and ld) . To assess whether CD40 was expressed by macrophages within the plaque, double staining was performed for CD40 (blue in Figure d ) and acid phosphatase, a lysosomal enzyme characteristic for macrophages (red in Fig. d) We argue that CD40-CD40L interactions could affect the atherosclerotic process at different levels, including transmigration of mononuclear cells into plaque areas; activation of T cells and cytokine production; activation of several macrophage effector functions; local antigen presentation; tissue restructuring through combined activities of T cells, macrophages, and fibroblasts.
The role of CD40 on endothelium, transmigration of cells, and production of cytokines by T cells has been addressed in the preceding section on EAE. The macrophage effector functions activated by CD40 ligation that may be operational in atherosclerotic plaques include adherence to CD40L-expressing cells, homotypic aggregation, and increased survival of cells, probably through protection from apoptosis Alderson et al., 1993) . Furthermore, the antigenpresenting function can be improved through upregulation of accessory molecules (ICAM-1, MHC class II, B7-2, and CD40). With regard to bioactive compounds, CD40 ligation can costimulate NO production and secretion of the proinflammatory cytokines TNF-c, IL-1/3, IL-6, IL-8, and IL-12 (see Table and references cited before). CD40L can also induce production of gelatinase B by monocytes and fibroblasts (Malik et al., 1996) . Interestingly, by this mechanism, macrophages can digest collagen present in the fibrous cap of atherosclerotic plaques, and as such may contribute to fissure and release of the cap, leading to life-threatening occlusions of arteries (Galis et al., 1994) . Fibroblasts express CD40 (Fries et al., 1995) and proliferate in response to CD40L signals (Yellin et al., 1995) 
